* DarioHealth Corp DRIO.OQ DRIO.O is expected to show a
fall
in quarterly revenue when it reports results on May 15 for the
period ending March 31 2024
* The New York City-based company is expected to report a
4.4% decrease in revenue to $6.758 million from $7.07 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for DarioHealth Corp is for
a loss
of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.
* Wall Street's median 12-month price target for DarioHealth
Corp
is $5.00, above its last closing price of $1.60.
This summary was machine generated May 7 at 14:45 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)